biostudies-literatureUnknown7(6)Nakamura MRegeneron PharmaceuticalsSanofi<h4>Introduction</h4>The present study is the largest registry study ever conducted in Japan exploring the prevalence of familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). Our study aims to (1) evaluate the status of lipid management and the subsequent risk of major cardiovascular events following hospitalisation of Japanese patients with ACS in real-world clinical practice; (2) determine the proportion of Japanese patients with ACS who achieve the lipid management goal and have a reduction of event risks with strict lipid management (low-density lipoprotein-cholesterol <1.81 mmol/L); (3) determine the prevalence of FH and (4) investigate the clinical significance of proprotein convertase subtilisin kexin 9 (PCSK9) level.<h4>Methods and analysis</h4>We wBMJ opene014427https://www.ebi.ac.uk/biostudies/studies/S-EPMC5734360biostudies-literatureExploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.PMC5734360Uno KNakamura MHarada-Shiba MAko JNohara AHirayama AArai HfalseExploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.<h4>Introduction</h4>The present study is the largest registry study ever conducted in Japan exploring the prevalence of familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). Our study aims to (1) evaluate the status of lipid management and the subsequent risk of major cardiovascular events following hospitalisation of Japanese patients with ACS in real-world clinical practice; (2) determine the proportion of Japanese patients with ACS who achieve the lipid management goal and have a reduction of event risks with strict lipid management (low-density lipoprotein-cholesterol <1.81 mmol/L); (3) determine the prevalence of FH and (4) investigate the clinical significance of proprotein convertase subtilisin kexin 9 (PCSK9) level.<h4>Methods and analysis</h4>We w2017-01-01T00:00:00Z2017 Jul2025-04-19T18:45:48.124Z2019-03-26T22:46:35ZS-EPMC57343602867413210.1136/bmjopen-2016-014427